A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Evobrutinib (Primary) ; Dimethyl fumarate
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 04 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 28 Jun 2017 Planned End Date changed from 1 Mar 2019 to 27 Feb 2019.
    • 28 Jun 2017 Planned primary completion date changed from 1 Mar 2019 to 27 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top